| Autor: |
Lo Russo, Giuseppe, Macerelli, Marianna, Platania, Marco, Zilembo, Nicoletta, Vitali, Milena, Signorelli, Diego, Proto, Claudia, Ganzinelli, Monica, Gallucci, Rosaria, Agustoni, Francesco, Fasola, Gianpiero, de Braud, Filippo, Chiara Garassino, Marina |
| Zdroj: |
Current Drug Targets; March 2017, Vol. 18 Issue: 3 p341-362, 22p |
| Abstrakt: |
Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among all lung tumors, small cell lung cancers account for about 20%. Patients typically include heavy smokers in 70s age group, presenting with symptoms such as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the time of diagnosis. A useful and functional classification divides small cell lung cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy is the standard treatment for limited disease, with improved survival when combined with prophylactic cranial irradiation. Platinum compounds (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive disease. Nevertheless, despite high chemo- and radio-sensitivity of this cancer, nearly all patients relapse within the first two years and the prognosis is extremely poor. A deeper understanding about small cell lung cancer carcinogenesis led to develop and test a considerable number of new and targeted agents but the results are currently weak or insufficient. To date, small cell lung cancer is still a challenge for researchers. In this review, key aspects of small cell lung cancer management and controversial points of standard and new treatments will be discussed. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
